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Running title: Imatinib-induced reproductive defects in zebrafish 16 
 17 
Abstract – Imatinib (IM) is a tyrosine kinase (TK) inhibitor (TKI) used to treat chronic 18 
myeloid leukemia. Clinical case reports and a few laboratory mammal studies provide 19 
inconclusive evidence about its deleterious effects on reproduction. The aim of the current 20 
study was to evaluate the potential of zebrafish to characterize IM-induced effects on 21 
reproduction and clarify IM effects on reproductive success. To this end, we exposed adult 22 
zebrafish to four concentrations of IM for 30 days followed by a 30-day depuration period. 23 
IM exposure caused a concentration-dependent, irreversible, suppression of folliculogenesis, 24 
reversible decrease in sperm density and motility, decreased fecundity and fertility, but no 25 
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significant change in atretic follicle abundance. We also observed IM-induced premature 26 
hatching, but no significant change in embryo-larvae survivability. However, we found 27 
significant IM-induced morphometric malformations. IM decreased expression of vegfaa and 28 
igf2a (two reproductive-, angiogenic-, and growth-related genes) in testes and ovaries. The 29 
results demonstrate IM can induce significant changes in critical reproductive endpoints and 30 
zebrafish as a suitable model organism to show effects of IM on reproduction. The findings 31 
suggest that TKI effects on reproductive success should be considered.  32 
 33 
Keywords:  igf2a, Imatinib, Reproduction, vegfaa, Zebrafish  34 
 35 
1. Introduction 36 
Imatinib mesylate (IM) is a tyrosine kinase (TK) inhibitor (TKI) (Loren et al., 2013) 37 
developed in the mid-1990s (Heinrich et al., 2000). It was first used in 1998 to treat chronic 38 
myeloid leukemia (CML) (Mughal and Schrieber, 2010) and has since become a standard 39 
therapeutic agent against CML (Ault et al., 2006). IM is the first in a family of highly 40 
effective, minimally toxic, agents widely used to treat CML (Zamah et al., 2011). 41 
IM is not specific for Bcr-Abl (a gene often found in CML patients that codes for a 42 
TK protein) and binds to at least 25 kinases with varying affinities (Karaman et al., 2008), 43 
e.g. KIT, platelet-derived growth factor receptor (PDGFR), abelson-related gene (ARG), and 44 
Colony-stimulating factor-1 receptor (c-FMS). These proteins are known to have functions 45 
that may play a role in gonadal development, embryo implantation, and fetal development 46 
(Tybulewicz et al., 1991; Mauduit et al., 1999; Soriano, 1994, 1997; Hoch and Soriano, 47 
2003). Proteomic analysis of IM-treated human ovarian cancer cells by Patel et al. (2008) 48 
showed that exposure of ovarian cells to IM produces complex intracellular changes. 49 
Cytotoxicity and genotoxicity of IM for zebrafish has been reported by Novak et al. (2017). 50 
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In early clinical case reports exposure to IM was associated with human ovary 51 
deficiencies, e.g. a greatly diminished follicle count (Christopoulos et al., 2008), a severely 52 
compromised ovarian response to gonadotropin stimulation, and compromised ovarian 53 
hormone production and oocyte recovery (Zamah et al., 2011). Results showed decreased 54 
numbers of primary follicles and developed Graafian follicles in rats (Yaghmaei et al., 55 
2009b), increased number of pyknotic bodies in mice (Kerr et al., 2012), and increased 56 
apoptosis rate in human oocytes (Bildik et al., 2016). 57 
In contrast, there are human clinical case reports, e.g. Malozowski et al. (2008) and 58 
reviewed in Hensley and Ford (2003) as well as studies with laboratory animals (Schultheis et 59 
al., 2012), in which IM exposure was not correlated with gonadal defect. There are also 60 
controversial clinical case reports on IM congenital effects. Some were reviewed by Hensley 61 
and Ford (2003), Ali et al. (2006), and Apperley (2009). The above reports provide 62 
inconclusive evidence about deleterious effects of IM on reproduction. There is variation 63 
among the studies concerning species, age, maturation status, gender, and exposure regimen 64 
(e.g. dose, and exposure duration) that most likely contribute to the varying reported 65 
observations. Christopoulos et al. (2008) suggested that awareness of the potential for 66 
reproductive toxicity will enable physicians to offer patients appropriate counseling and to 67 
consider strategies to preserve fertility before prescribing IM chemotherapy. 68 
Zebrafish are the third most frequently used laboratory animal (Goldsmith and Solari, 69 
2003) in a variety of biomedical research fields (e.g., toxicology, drug discovery, and 70 
fertility) (Hoo et al., 2016). The use of zebrafish is consistent with the ‘3Rs’ (reduce, refine 71 
and replace) approach of animal use for scientific purposes, potentially replacing animals 72 
such as mammals with vertebrates that are considered lower on the phylogenetic scale (The 73 
Guide, 2011).  74 
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The aims of this study were to analyze adverse effects of IM on 1) zebrafish ovarian 75 
follicle development, histopathology, and fecundity, 2) sperm density and motility; 3) 76 
viability parameters (fertility, embryo hatchability, and embryo-larvae survivability), 4) 77 
larvae morphologic and morphometric malformations, 5) the dose-response of IM-induced 78 
reproductive symptoms and their potential reversibility, and 6) the expression of vascular 79 
endothelial growth factor Aa [vegfaa] and insulin-like growth factor 2a [igf2a]). 80 
Gonadal development is a complicated process in reproduction in which various 81 
genes, biochemical and signaling pathways, and hormonal axes (endocrine, paracrine, and 82 
autocrine) are involved. Therefore, selection of specific genes that might explain IM-induced 83 
changes in the current study aims was an important challenge. Vegfaa and igf2a (as 84 
angiogenic-, reproductive- and growth-related genes) were selected. Inhibitory effects of IM 85 
on vegf (Legros et al., 2004; Raimondi et al, 2014) and igf2 (Pink et al., 2005; Belinsky et al., 86 
2008; de Waal, 2009) have been reported. 87 
 88 
2. Materials and methods 89 
2.1. Fish culture 90 
Wild-type zebrafish (6 months) were purchased from a local supplier in the North of 91 
Iran. The fish have been raised through multiple generations within our facility. Care was 92 
taken to select zebrafish with continuously high egg production (King Heiden et al., 2006) 93 
and fertilization rate (Braunbeck and Lammer, 2006). For fish housing and maintenance see 94 
Samaee et al. (2015). Zebrafish were used and cared for in accordance with standard 95 
protocols and guides (Westerfield, 2007; Guide for the Care and Use of Laboratory Animals, 96 





2.2. Preparation of IM suspension 100 
IM (Gleevec®; 100 mg/tablet) was obtained from Osvah Pharmaceutical Co. (Tehran, 101 
Iran). Two tablets were ground using a mortar and pestle and the resulting powder was added 102 
to 500 mL of 2.5% NaCl [Merck] solution yielding 0.4 mg mL-1 IM. The suspension was 103 
sonicated (power: 70%; duty: 50%) for 30 min (resulting in a homogeneous cloudy 104 
suspension). The IM dose was based on the average human dose of 600 mg/day to control 105 
CML (Ohyashiki et al., 2002; James et al., 2003; Prabhash et al., 2005; Christopoulos et al. 106 
2008; Pye et al., 2008; Zamah et al., 2011; Bay et al., 2013), equal to 8 mg per kg in a human 107 
of 75 kg. Fifty mL IM-BSN suspension (0.4 mg IM mL-1 [see section “2.5”]) was added to 108 
1950 mL tank water (see section “2.6”) providing fish with a nominal concentration of 10 μg 109 
IM mL-1.  110 
To ascertain the effects of IM tablet excipients a mix of all the excipients minus the 111 
active substance was obtained from Osvah Pharmaceutical Co. Zebrafish were exposed to the 112 
excipients in 3 replicates of 10 zebrafish. Endpoints such as the abundance of follicular 113 
stages, fecundity, and sperm density and motility were considered to evaluate the biological 114 
effects of the excipients. 115 
 116 
2.3. Production of brine shrimp nauplii (BSN) feed for the zebrafish 117 
BSN were prepared using the cyst of Artemia franciscana, strain VC, obtained from 118 
Can Tho University. The cysts were cultured, hatched overnight, harvested, cleaned, and 119 
resuspended as described (Varga, 2011). The total number of BSN in 500 mL cleaned 120 






2.4. Preparation of “BSN suspension” 125 
A determined number of harvested BSNs were washed in a 100 mL glass cylinder 126 
with 2.5% salt water, adjusted to 100 mL with 2.5% salt water, and the “BSN suspension” 127 
stored at 4 °C with moderate aeration until use.  128 
 129 
2.5. Preparation of “IM-BSN suspension” 130 
A determined number of harvested BSNs were washed in a 500 mL glass cylinder 131 
with 0.4 mg mL-1 “IM suspension” (see section 2.2), adjusted with “IM suspension” to 500 132 
mL, and the “IM-BSN suspension” moderately and continuously aerated at 28 °C for less 133 
than 1 hour.  134 
The Artemia nauplii used to prepare the IM-BSN suspension were newly hatched that 135 
grow on their yolk sac, don’t externally feed, and therefore don’t take up IM (Van Stappen, 136 
1996), obviating drug metabolism. BSN is a live attractive food for zebrafish. When zebrafish 137 
feed on BSN they also ingest the IM suspension. This approach differs from most adult 138 
zebrafish drug delivery studies that used direct addition to water (e.g. Maley et al., 2013; 139 
Samaee, 2015; Dr. Kiranam Chatti, University of Hyderabad, India [2018], personal 140 
communication). 141 
 142 
2.6. IM exposure procedure  143 
Zebrafish were housed in 5 L mouse Plexiglas cages (Razirad Co, Iran) Samaee et al. 144 
(2015). Treatment groups were defined by the frequency of zebrafish feeding with “IM-BSN 145 
suspension” and “BSN suspension” for 1 month as follows: 146 
“IM-0” (control group): 3 feedings per day with BSN only (1, 5, and 9 h after light 147 
on). “IM-1”: received a single (1 h after light on) IM-BSN feeding, and 2 regular BSN 148 
feedings. “IM-2”: received 2 IM-BSN feedings and 1 BSN feeding. “IM-3”: received 3 IM-149 
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BSN feedings per day. Each treatment was performed in 3 replicates (with a total of 20 150 
zebrafish per replicate).  151 
For feedings, the tank filter unit was switched off and some tank water discarded so 152 
that 1950 mL water remained per tank. Fifty mL of BSN suspension was added (with or 153 
without IM). We allowed fish 1 h (Maley et al., 2013) to consume nauplii, thereafter the tank 154 
water was completely changed.  155 
IM-induced reproductive endpoint changes were evaluated at two time points: 1) at 156 
the end of the IM exposure period, and 2) after 1 month of IM depuration (to assess recovery 157 
from IM exposure effects). 158 
 159 
2.7. Validation of IM presence in zebrafish tissue 160 
IM-treated fish brains were collected and extracted according to Zhang et al. (2016). 161 
Analyses were performed with Waters Alliance 2695 HPLC-Micromass Quattro micro API 162 
Mass Spectrometer. LC conditions – mobile phase: MeOH + 0.1% Formic Acid and H2O, 163 
column: Atlantis T3-C18 3µ, 2.1×100 mm, column temperature: 30  ̊C, flow rate: 0.2 164 
mL/min, and injection volume: 10 µL. MASS conditions – mode: ESI+, cone Volt: 45 V, 165 
capillary Volt: 3 kV, extractor: 3 V, RF lens: 0.2 V, collision Energy: 35 eV, gas nebulizer: 166 
N2 (grade 5), flow gas: 200 L/h, source temperature: 150   ̊C, and desolvation temperature: 167 
350   ̊C. 168 
 169 
2.8. Ovarian histology and morphology  170 
Fish were collected after one month of IM exposure and 1 month after IM treatment 171 
was stopped. At least six females (King Heiden et al., 2006) from each treatment and control 172 
group were fasted (for 24 h) then euthanized (Gupta and Mullins, 2010). The fish were 173 
decapitated, tails removed, an incision made along their ventral surface, and fixed in 10% 174 
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formaldehyde (Samaee et al., 2009). Fixed specimens were decalcified by placing them in a 175 
decalcifying buffer (5 mL formic acid, 5 mL formaldehyde, and 90 mL dH2O) for one week 176 
at room temperature. Specimens were dehydrated in a graded series of ethanol, cleared in 177 
xylene, and embedded in paraffin. For each specimen, 4-6 distinct sagittal sections at 5 μm 178 
(taken every 20 μm) from the same region, were transferred onto microscopy slides, stained 179 
with hematoxylin and eosin, and cover slipped. Sectioning was standardized according to the 180 
relative position of the organ of interest to other structures (Fig. 1b). Sections were examined 181 
under a light microscope (C82612, Olympus, Japan) equipped with a digital camera (CMEX 182 
DC. 1300, Netherlands) at 100× and 400× magnification. 183 
Ovarian follicles were counted and assigned their appropriate gametogenic stage (Fig. 184 
2), based on morphological characteristics as defined by Selman et al. (1993) and Silva et al. 185 
(2012).  The relative number of follicles at each of the five gametogenic stages/total follicles 186 
counted × 100 was calculated (= frequency), based on more than 100 follicles in each ovary 187 
(Wang et al., 2011). Images were recorded at 100× and 400× magnification Ovarian follicle 188 
diameter was determined on digital photomicrographs using Image Focus (V. 13, Euromex 189 
Microscopen b.v., 2005-2006). For each specimen and each follicular stage, we determined 190 
the diameter of 10-12 follicles. The identification of atretic follicles and determination of 191 
their atresia level (the degeneration of ovarian follicles that do not ovulate), was performed 192 
according to Miranda et al. (1999) after discussing with several fish histopathologists. 193 
 194 
2.9. Sperm analysis 195 
Fish were fasted for 24 h (Kinkel et al., 2010), anesthetized with cloves (see Grush et 196 
al., 2004; half teaspoon of blended dried flowering clove buds, Eugenia caryophyllata, in 250 197 
mL of system water for ~ 1 min), euthanized, rinsed in fresh water, blotted, weighed (Yang et 198 
al., 2007), and immersed in Hank’s balanced salt solution (HBSS) (Hagedorn and Carter, 199 
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2011) (in a ratio of ~ 1:50 [mass:volume]) (Dr. Huiping Yang, LSU AgCenter, personal 200 
communication). The testes were minced in HBSS (Ingermann et al., 2011) with fine 201 
scissors. Testes pieces were gently aspirated into and ejected from an Eppendorf pipette > 20 202 
times to disrupt the tissue and to release mature sperm cells. Large testes fragments were 203 
removed with fine forceps, or by a 30 s spin to isolate heavy tissue fragments from the 204 
supernatant suspension (Dr. Qiaoxiang Dong, Institute of Watershed Science and 205 
Environmental Ecology, China, personal communication). The resulting suspension 206 
containing sperm can be held on ice for ≤ 2 h (Westerfield, 2000; Hagedorn and Carter, 207 
2011). 208 
Sperm density was determined using a hemocytometer. A bright field microscope 209 
(Eclipse E600, Nikon, Japan) equipped with a digital camera (Cyber-shot DSC-W130 8.1MP 210 
Digital Camera with 4x Optical Zoom with Super Steady Shot, Sony, Japan) was used to 211 
record sperm motility. The recordings were analyzed using EDIUS 6 and the percentage of 212 
motile sperm within 5, 10, 15, 20, 25, and 30 s after activation, start of sperm movement after 213 
adding water, (denoted spa [seconds post activation]) determined. 214 
 215 
2.10. Breeding, embryo collection, and fecundity and fertility determination 216 
Fish breeding, embryo collection and culture, determination of fecundity, 217 
embryo/larvae viability parameters (fertilization rate [FR], hatching rate [HR], and 218 
survivability rate [SR]), and recording of morphometric characteristics (MC) were carried out 219 
according to Samaee et al. (2019). For the breeding trials, 16 zebrafish (8 males and 8 220 
females) were taken from the treated (IM-3) and 16 from the untreated (IM-0) groups (Fig. 221 
1c-f). To further investigate the effects of IM in both sexes, male and female replacement 222 
experiments were conducted. For the male replacement trial eight untreated males were 223 
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housed with IM-3 treated females [Fig. 1e]). For the female replacement trials, eight 224 
untreated females were placed with IM-3 treated males [Fig. 1f]). 225 
 226 
2.11. Gene expression analysis 227 
Ovary/testis pieces were snap frozen in liquid nitrogen and stored at -80 ºC until use. 228 
Six specimens from each treatment group were used for gene expression analysis. Total RNA 229 
was extracted using a Bio FACTTM Kit (RP101- 050, Daejeo, Korea) following the 230 
manufacturer’s instructions, eluted in 20 μL RNase-free water, its quality/quantity 231 
determined by spectrometry (NanoDrop-Thermo 2000C; Thermo Fisher Scientific, 232 
Wilmington, DE, USA), then stored at -80 °C. Total RNA (10 ng) was reverse transcribed 233 
into cDNA using a BioFACTTM Kit (BR441-096, Daejeo, Korea) in a 20 μL reaction volume 234 
by a thermal cycler (model, PEQLAB, Germany), cDNA quantity evaluated by spectrometry, 235 
and stored at -20 °C.  236 
Two target genes (vegfaa and igf2a) and a housekeeping genes (glyceraldehyde-3-237 
phosphate dehydrogenase [gapdh]), as internal standards for the target genes, were used for 238 
gene expression analysis. The primers were designed with Primer Express Software (Applied 239 
Biosystems) using identical parameters to generate amplicons of similar size. The primers 240 
were synthesized by Metabion International AG (Germany).  241 
Quantitative real-time PCR was performed using the StepOne PlusTM system (Applied 242 
Biosystems, Foster City, CA, USA). Each reaction contained 0.5 μL diluted cDNA, 0.05 μL 243 
forward (10 μM) and 0.05 μL reverse (10 μM) primers, and 10 μL SYBR Green PCR Master 244 
Mix to a final volume of 20 μL. Amplification followed the PCR cycle condition: 95 ºC for 245 
10 min, followed by 40 cycles of 15 s at 95 ºC and 1 min at 61 ºC. Each treatment was 246 
analyzed in triplicate (biological replicates) and each sample in triplicate (methodological 247 
replicates). A non-template control was performed to ensure that only one PCR product 248 
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amplified and the stock solutions were not contaminated. Cycle conditions and amounts of 249 
templates were optimized for each primer set in pilot experiments to ensure that amplification 250 
was terminated within the linear phase.  251 
A melting curve was also performed to ensure the specificity of PCR amplification. 252 
The melt curve protocol was 15 s at 95 °C once and then 10 s each at 0.3 °C increments 253 
between 60 °C for 1 min and 95 °C for 10 min. Data collection was enabled at each 254 
increment of the melt curve. The amplification efficiency, specificity of primers, and amount 255 
of cDNA/sample were tested by the standard curve method. Primer pairs were deemed to be 256 
acceptable for analysis if they generated standard curves with an r2 value above 0.98, there 257 
was consistency among replicates and the primer amplification efficiency was 85–110%.  258 
RNA expression levels are presented as cycle threshold values. The relative 259 
expression of genes was calculated by the 2–ΔΔCT method (Livak and Schmittgen, 2001) using 260 
gapdh. The gapdh did not change among different treatments in any of the experiments.The 261 
expression levels of the vegfaa and igf2a were evaluated relative to gapdh. IM-3 treated fish 262 
igf2a and vegfaa gonad expression level was evaluated relative to untreated fish.  263 
 264 
2.12. Statistical analysis 265 
Values are reported as mean ± S.D. Differences among treatment groups were 266 
evaluated by one-way analysis of variance followed by Duncan’s multiple range test (post-267 
hoc) for all endpoints. A p-value of 0.05 was used to set statistical significance levels. Simple 268 
regression models were formulated between endpoint magnitudes and the IM exposure 269 
frequency to identify concentration-dependent IM-related effects. The levels of significance 270 
(≤ 0.002 [for gonadal parameters] and p ≤ 0.003 [for morphometric ratios]) for the regression 271 
analyses were selected after applying the Bonferroni's adjustment to minimize the chance of 272 
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type I statistical error. All analyses were performed using IBM SPSS (version 20; SPSS Inc., 273 
Chicago, IL, USA), and Excel 2010 (Microsoft Corporation, Redmond, WA, USA). 274 
 275 
3. Results 276 
3.1. Effects of IM tablet excipients on reproductive endpoints  277 
No significant difference was observed between tablet excipient-treated zebrafish 278 
(e.g. abundance of follicular stages [e.g. PN; 11.6 ± 2.0%], fecundity [160.8 ± 23.1], sperm 279 
density [4.2713 × 108 ± 7.29971969 × 107 per mL], and sperm motility [e.g. 5 spa; 77.4 ± 280 
10.3%]) and controls (e.g. abundance of follicle stages [e.g. PN; 10.6 ± 1.4%], fecundity 281 
[154.8 ± 16.4], sperm density [4.490750000 × 108 ± 6.03184000 × 107 per mL], and sperm 282 
motility [e.g. 5 spa; 80.1 ± 4.0%]) concerning the evaluated reproductive endpoints in the 283 
current study. 284 
 285 
3.2. Presence of IM in tissue  286 
Zebrafish brain IM was 0.08 ± 0.02 ng mg-1. An IM plasma level of > 0.5 μg mL-1 287 
(0.5 ng mg-1) is needed for tyrosine kinase inhibition in vitro (Peng et al., 2005), > 1,000 ng 288 
mL-1 (1 ng mg-1) to control GIST and CML (Eechoute et al., 2011), and 0.25 μM to achieve 289 
50% inhibition of cellular Bcr/Abl-related tyrosine phosphorylation (Wolff et al., 2003). IM 290 
crosses an intact blood–brain barrier poorly (Holdhoff et al., 2010). In the study of Wolff et 291 
al. (2003) mice received 150 mg kg-1 IM daily orally. Plasma IM was 6958 ng mL-1, 155 292 
times higher than in the cerebral spinal fluid (CSF) (45 ng mL-1). In Azanza et al. (2018) the 293 
IM concentration of CSF was 74 times lower than in the plasma. Therefore, related to the 294 
brain IM concentration in the current study the IM level in zebrafish plasma was probably at 295 




 3.3. Frequency of ovarian follicular stages  298 
Ovaries of zebrafish treated 1, 2, or 3 times per day with IM had significantly more 299 
follicles at the PN stage than controls (Fig. 3a), but significantly fewer follicles at eCA, 300 
mCA, V, and M stages (Fig. 3b to e). The number of ovarian follicles at the PN stage [Fig. 301 
4a] positively correlated and at the eCA, mCA, V, and M stages [Fig. 4b to e] with the daily 302 
IM exposure frequency.  303 
We only found a statistically significant difference between IM-treated fish at the end 304 
of IM exposure and the depuration period regarding the proportion of follicles at the mCA 305 
stage [Fig. 5c]. At the end of depuration there were non-significant trends toward fewer 306 
follicles at eCA and V (Fig. 5b and d), and more follicles at PN, mCA, and M (Fig. 5a, c and 307 
e) stages. 308 
 309 
3.4. Follicle diameter  310 
IM-1, 2, and 3 treated zebrafish ovary follicle diameters at PN, eCA, mCA, V, and M 311 
(Fig. 3 f to j) stages were consistently smaller compared to controls (IM-0), in some cases 312 
significantly. We found a significant, negative linear relationship between the diameter of 313 
follicles at the M stage and the frequency of IM exposure (Fig. 4j). Although a negative linear 314 
relationship was also observed for the other follicular stages (PN, eCA, mCA, and V [Fig. 4f 315 
to i]), the correlations were not statistically significant.  316 
There were no significant differences between the two time-points regarding the 317 
diameter of follicles at gametogenic stages (eCA, mCA, V, and M [Fig. 5g to j]). After the 318 
depuration period, treated zebrafish had significantly smaller PN (Fig. 5f), non-significantly 319 





3.5. Fecundity 323 
A significant decrease in fecundity was observed in IM-treated (108 ± 28) zebrafish 324 
compared to untreated specimens (control; IM-0, 171 ± 55). The IM-induced decrease in 325 
female fecundity did not recover after the 1-month drug depuration period (104 ± 19). 326 
 327 
3.6. Sperm density and motility 328 
The highest and lowest sperm densities were observed in IM-0 (control) and IM-3 329 
treated zebrafish, respectively (Fig. 6a). There was a significant and negative linear 330 
relationship between zebrafish sperm density and IM exposure frequency (Fig. 7a).  331 
The highest motility was observed in IM-0 and the lowest motility in IM-3 treated fish 332 
at all observation times (Fig. 6b-g). There was a significant decline in the percentage of 333 
motile sperm with time (i.e. from 5 to 30 spa) in both IM-treated and untreated zebrafish. 334 
There was a significant and negative linear relationship between sperm motility and IM 335 
exposure frequency (Fig. 7b-g).  336 
The IM-induced decrease in sperm density and motility recovered during the 337 
depuration period. At the end of the depuration period sperm cells in IM-1, IM-2, and IM-3 338 
treated fish had a density and motility similar to that of untreated fish (IM-0) (results not 339 
shown).   340 
 341 
3.7. Viability  342 
3.7.1. Fertility 343 
There was a significant fertility difference between IM-3♀ × IM-3♂ pairs and 344 
controls (IM-0♀ × IM-0♂) (Fig. 1c and d). In the male replacement (IM-3♀ × IM-0♂) and 345 
female replacement (IM-0♀ × IM-3♂) trials the fertility rate partially recovered (Fig. 1e and 346 
f). There was a significant difference between the male replacement (IM-3♀×IM-0♂) and 347 
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control (IM-0♀ × IM-0♂) although such a significant difference was not observed between 348 
female replacement (IM-0♀ × IM-3♂) and control. 349 
 350 
3.7.2. Embryo hatching rates 351 
The IM-3♀ × IM-3♂ embryos had a significantly higher HR at 48 hpf compared to 352 
IM-0♀ × IM-0♂ embryos. A significant difference was not observed in HR at 72 hpf. In the 353 
male replacement trial, the IM-3♀ × IM-0♂ embryos had a 48 hpf HR -lower than IM-3♀ × 354 
IM-3♂ and higher than IM-0♀ × IM-0♂ embryos. In the female replacement trial, the IM-0♀ 355 
× IM-3♂ embryos had a 48 hpf HR lower than IM-3♀ × IM-3♂ and IM-3♀ × IM-0♂ 356 
embryos, similar to IM-0♀ × IM-0♂ embryos. We observed no such difference in HR at 72 357 
hpf (Fig. 1c-f). 358 
 359 
3.7.3. Embryo-larvae survival rate  360 
We found no significant difference in 24-240 hpf embryo-larvae survivability 361 
between IM-3♀ × IM-3♂ (mean ± S.D; 88.2 ± 7.7%) and IM-0♀ × IM-0♂ (mean ± S.D; 89.5 362 
± 11.0%) progeny. We also did not find any significant difference in 24-240 hpf embryonic 363 
or larval survival rates between the offspring of replacement trials (male [IM-3♀ × IM-0♂; 364 
95.8 ± 1.2%] and female [IM-0♀ × IM-3♂; 99.2 ± 1.2%]) and IM-3♀ × IM-3♂ (88.2 ± 7.7%) 365 
and IM-0♀ × IM-0♂ (89.5 ± 11%). 366 
 367 
3.8. Larvae morphometric alterations  368 
The IM-exposed groups significantly differed from controls for changes in 369 
morphometric ratios at different larval developmental stages (Table 1). In Table 1 all ratios 370 
but one (row 19) were different for at least one IM treatment group from control. Significant 371 
variations were also observed among all but 4 IM-exposed groups (Table 1, rows 11, 15-16, 372 
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and 18). The variations of 19 morphometric ratios (as dependent variables) at 72, 96, 120, 373 
144, 168, 192, and 240 hpf were significantly correlated to the frequency of exposure to IM 374 
(as the independent variable) by simple regression models as either linear (Table 2, boldface 375 
data) or quadratic (Table 2, underlined data) functions. 376 
 377 
3.9. IM-induced changes in vegfaa and igf2a expression  378 
The expression levels of igf2a and vegfaa were significantly down-regulated in the 379 
ovary of IM-3-treated adult zebrafish relative to untreated fish (IM-0), by 2.10- and 2.30-fold, 380 
respectively. A decreased expression level of these four endpoints was also observed in the 381 
testes of IM-3-treated adult zebrafish relative to untreated fish, by 2.13-fold and 2.30-fold, 382 
respectively. 383 
 384 
4. Discussion  385 
IM is a class of chemotherapeutic agents with inconclusive reports about its adverse 386 
effects on reproduction of humans and laboratory animals. In the current study, for the first 387 
time, zebrafish were used as an alternative model to characterize potential IM-induced 388 
reproductive effects.   389 
 390 
4.1. Effects of IM on ovary development 391 
Exposure to IM caused a delay in zebrafish ovarian follicular development that was 392 
indicated by the significantly higher presence of early-stage perinucleolar follicles in all three 393 
IM-treated groups and a suppression of size in the IM-3 treated group compared to control. In 394 
the study of Asadi-Azarbaijani et al. (2017) the treatment of rats on postnatal days 2–4 with 395 
IM (150 mg/kg) led to delay in the formation of primordial follicles, increased density of 396 
multi-oocyte follicles, oogonia, and germline clusters, and decreased activation of primordial 397 
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follicles. In brief, the follicular defect was attributed to the inhibitory effect of IM on 1) TK 398 
signaling pathways, 2) growth factors, 3) transcription factors, and 4) steroidogenic 399 
regulatory proteins that are involved in early folliculogenesis. The inhibiting effect of IM on 400 
follicle activation in the Asadi-Azarbaijani et al. (2017) study is also supported by a study 401 
that showed significantly decreased numbers of primary follicles, developing Graafian 402 
follicles, and developed Graafian follicles in adult IM-treated (50 and 100 mg/kg for 14 days) 403 
rats (Yaghmaei et al., 2009b). 404 
There are also studies in which the exposure to IM led to a significant decrease in 405 
total number of ovarian follicles, e.g. a massive follicle loss was reported in IM-treated (2.5, 406 
5, and 10 µM for 12, 24, 48 and 72 h) ovaries from humans (Bildik et al., 2016). Yildiz et al. 407 
(2016) also cited a significant decrease in the ovarian follicle number in IM-treated (25 408 
mg/kg/day for 14 days) rats.  409 
Christopoulos et al. (2008) reported a single case of a 28-year old woman with CML 410 
who developed primary ovarian insufficiency after treatment with 400–600 mg/day IM for 2 411 
years although the report was criticized by Malozowski et al. (2008) as possibly being only a 412 
chance finding. In the study of Schultheis et al. (2012) IM (150 mg/kg/day for 2 months) had 413 
no effect on murine ovary. There was a normal succession of follicle development from the 414 
primordial stage to ovulation in leukemic mice. 415 
In the current study, IM-induced defects in folliculogenesis were concentration-416 
dependent (Fig. 4a-e) and consistent with the study of Bildik et al. (2016) in human ovaries. 417 
The overall statistical strength of the association was higher at later follicular stages (V and 418 
M [Fig. 4d and e]) compared to earlier stages (PN, eCA, and mCA [Fig. 4a-c]), which can be 419 
explained by follicles at advanced maturity stages having a higher probability of being atretic 420 
(Silva et al., 2012), and therefore more sensitive to IM than earlier gametogenic stages. 421 
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In our study, the exposure to IM led to a decrease of the diameter of PN, mCA, and M 422 
follicles, and a non-significant decrease in the diameter of eCA and V follicles, compared to 423 
controls, i.e. a decrease in follicle diameters at all gametogenic stages.  424 
Although the smaller follicles in the current study at later gametogenic stages are 425 
thought of as a disadvantage for the offspring (Weber et al., 2003), the biological effects of 426 
the decrease in the size of follicles at earlier stages (i.e. PN and eCA, Fig. 4f and g) remains 427 
unclear.  428 
Cortical alveoli are synthesized endogenously, involving the rough endoplasmic 429 
reticulum (ER) and the Golgi complex (Tyler and Sumpter, 1996). Adverse effects of IM on 430 
ER function (i.e. the induction of ER stress) have previously been reported (Hu et al., 2012). 431 
Thus, the decrease CA follicle size in the ovaries of IM-treated zebrafish compared to control 432 
in the current study can be correlated to adverse effects of IM on ER function.    433 
Except for the percent of oocytes in the mCA stage and PN diameter (Fig. 5 c and f) 434 
we did not find significant differences between the end of the 30-day IM exposure and after 435 
30 days of depuration regarding follicular development (follicle number [Fig. 5a-b, d-e], and 436 
diameter [Fig. 5g-j]) at the different gametogenic stages. This suggests that IM may have 437 
irreversible effects on zebrafish folliculogenesis after exposure.  438 
 439 
4.2. Sperm density and motility 440 
Zebrafish IM exposure led to a significant concentration-dependent decrease in sperm 441 
density and motility (Figs. 6 and 7). This is consistent with adult rat and human studies. 442 
Decreased sperm cell number at different gametogenic stages was seen in rats exposed to 6-443 
12 mg/kg for 30 days (Yaghmaei et al., 2009a). Sixty mg/kg of IM for 70 days reduced 444 
motile sperm number in rats (Novartis Pharmaceuticals Corporation, 2018). Oligospermia 445 
was seen in a human who received 400-800 daily for 5 months – Seshadri et al., 2004) and in 446 
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a human who received 400 mg daily for 35 months (Mariani et al., 2011). In contrast, no 447 
difference in spermatogenesis was observed in IM-treated and untreated adult mice 448 
continuously exposed to IM, 150 mg daily, for 2 months (see Apperley, 2009), and normal 449 
sperm production was seen in IM-treated leukemic mice (150 mg/kg/day for 2 months) 450 
(Schultheis et al. (2012)). The latter observation was attributed to the redundancy of the 451 
tyrosine protein kinase pools in gonads. A lack of IM-induced change in sperm motility was 452 
also observed in rats treated with ≤ 20 mg/kg attributed to the low IM dose (Novartis 453 
Pharmaceuticals Corporation, 2018). 454 
In the current study, the IM-induced decrease in sperm parameters recovered during 455 
the depuration period. This agrees with prior studies. An IM-induced 84% reduction in 456 
epididymal sperm in 35-day old mice that received 150 mg/kg IM from postnatal days 1 to 5 457 
returned to normal when 90 days old (Basciani et al., 2008)) and an IM-induced defect in 458 
spermatogenesis in immature rats (150 mg/kg on postnatal days 5 to 7) recovered by 11 459 
weeks of age (Nurmio et al., 2007).   460 
 461 
4.3. Viability  462 
We observed a significant fertility difference between IM-3♀ × IM-3♂ pairs and 463 
controls. In the male replacement (IM-3♀ × IM-0♂) and female replacement (IM-0♀ × IM-464 
3♂) trials, fertility recovered (increased). In contrast, fertility was not affected in female rats 465 
which had received less than the maximum clinical IM dose for 14 days before mating and 466 
through day 6 of gestation (Novartis Pharmaceuticals Corporation, 2018). 467 
The IM-3♀ × IM-3♂ subjects had a significantly higher hatching rate at 48 hpf 468 
compared to controls (IM-0♀ × IM-0♂) (55.2 vs, 0%). The lower hatching rate in male 469 
replacement trials (IM-3♀ × IM-0♂) (22.5%) and lack of hatching in female replacement 470 
trials (IM-0♀ × IM-3♂) (0%) at 48 hpf indicates that an effect of IM on eggs contributes to 471 
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accelerated hatching. The change in hatching time is an important stress response of fish 472 
larvae (Barton, 2002). Hatching is a consequence of hatching enzyme activity and embryo 473 
movements (Winnicki et al., 1970; Yamamoto, 1975). Zebrafish tyrosine kinase expression is 474 
regulated in the first 24 h of development, suggesting their role during early embryonic 475 
development (Challa and Chatti, 2013). The inhibitory role of IM on tyrosine kinases that 476 
control hatching events may contribute to the accelerated embryo hatching produced by IM-477 
treated fish.  478 
 479 
4.4. IM-induced changes in morphometric ratios 480 
There was significant variation between larvae produced by IM-treated and untreated 481 
zebrafish with respect to the morphometric measurements (as a sublethal response) (Table 1). 482 
The morphometric alterations were dependent on IM exposure frequency (Table 2). 483 
In comparison to morphological based toxicology assays, morphometric based assays 484 
are more relevant to fish larvae growth and developmental response to toxins. The MCs are 485 
used to assess impact on growth and development of larvae at exposure concentrations well 486 
below those that change larvae survival or produce any remarkable increase in gross 487 
malformations, as observed in the current study (Prof. Dr. Jennifer L. Freeman, School of 488 
Health Sciences, Purdue University; personal communication). 489 
IM-induced congenital malformations have been reported in animals and humans. 490 
Exposure of rats to IM (50 mg/kg/day) led to organogenesis defects, while such teratogenic 491 
effects were not observed in rabbits (Novartis investigator’s brochure and Novartis clinical 492 
safety statement [see Schultheis et al., 2012]). Two of 16 infants had minor abnormalities at, or 493 
shortly after, birth (Ault et al. (2006)). A study of 180 pregnancies by Pye et al. (2008) 494 
disclosed an IM-induced increase in the risk of fetal malformations. 495 
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In the current study three groups of IM-induced morphometric alterations were seen: 496 
The first group was present at early larval stages (BL/APB [Table 1, row 7], BL/BD2 [Table 497 
1, rows 8, and 13], PoPB/BD2 [Table 1, row 10], BD2/HL [Table 1, row 11], BD1/BD2 498 
[Table 1, row 15], and BD1/HL [Table 1, row 16]). The alterations disappeared at advanced 499 
stages. The second group occurred only at later larval stages (APB/HL [Table 1, row 19]). 500 
The third group was found to be stable through all larval stages (BL/BD1 [Table 1, rows 1, 3, 501 
6, 12, 18, 20, 23, and 25], APB/BD1 [Table 1, rows 2, 4, and 21], APB/BD2 [Table 1, rows 502 
5, and 22], BL/HL [Table 1, rows 9, and 24], and PoPB/BD1 [Table 1, rows 14, and 26]). 503 
The above-mentioned ratios were created from MCs related to body length (BL, HL, 504 
APB, and PoPB) and body depth (BD1 and BD2 [i.e. yolk depth/size]). Such MCs of 505 
zebrafish larvae have also been considered to characterize the toxicity of other agents (e.g. 506 
George et al., 2011; Brannen et al., 2010; Wirbisky et al., 2016). 507 
The second and third groups of morphometric ratio changes show the potential to 508 
characterize IM-induced responses. In general, a key element complicating the establishment 509 
of a link between exposure and a health defect is the time that elapses between exposure and 510 
response (Gluckman et al., 2008; Barouki et al., 2012). It may take years for an individual to 511 
present a health defect and pass it on to future generations (Jirtle and Skinner, 2007). In 512 
zebrafish the morphometric changes that appeared within a short period of exposure to 513 
different IM concentrations could predict later-in-life consequences of IM embryonic 514 
exposure. 515 
 516 
4.5. Changes in igf2a and vegfa expression 517 
Exposure of female zebrafish to IM led to retardation at the transition of follicles from 518 
the PN to the eCA stage (Fig. 3). These types of defects in ovary development have been 519 
reported in zebrafish treated with igf2a-inhibitors such as difenoconazole (Teng et al., 2017). 520 
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igf2a is dynamically expressed during folliculogenesis in zebrafish. Its expression starts to 521 
increase from the PN stage (> 0.1 mm), reaching its highest level in the eCA stage (~ 0.30 522 
mm) and then decreases (Li et al., 2015). Inhibitory effects of IM on the human igf2a 523 
homologue (igf2) have been reported (Pink et al., 2005; Belinsky et al., 2008; de Waal, 2009). 524 
The concurrent incidence of the transition retardation of ovarian follicles from the PN to the 525 
eCA stage with ovarian igf2a down-regulation in the IM treated zebrafish suggests a role of 526 
igf2a in the defect. 527 
In the current study, a decrease (~ 6-fold) was observed in the abundance of ovarian 528 
follicles at the V stage, i.e. a developmental block in follicular maturation to stage V (Fig. 3d). 529 
Recombinant zebrafish igf2a proteins directly enhance oocyte maturation via igf1 receptors 530 
(Li et al., 2015). In the zebrafish study of Nelson and Van Der Kraak (2010), recombinant 531 
human igf2 stimulated germinal vesicle breakdown in early vitellogenic (0.35–0.44 mm), 532 
midvitellogenic (0.45–0.56 mm), and full grown (0.57–0.65 mm) follicles incubated in vitro. 533 
igf2a also mediates luteinizing hormone (LH) action on oocyte maturation in zebrafish (Li et 534 
al., 2015). These observations may be attributable to either a direct effect of the IM-induced 535 
igf2a decrease on developing follicles or to an indirect disruption of the pituitary-gonadal 536 
endocrine system. Endocrine-related side effects of TKIs, e.g. alterations in thyroid function, 537 
bone metabolism, linear growth, gonadal function, fetal development, glucose metabolism, 538 
and adrenal function were reviewed by Lodish et al. (2010; 2013). The effects of IM on 539 
different parts of the reproductive endocrine axis in males and females have been seen, e.g. 540 
on progesterone, estrogen, follicle stimulating hormone (FSH), and LH concentration in 541 
the rat (Yaghmaei et al., 2009a and b), inhibin-B/FSH ratio in the human (Mariani et al., 542 
2008), and testosterone in the human (Gambacorti-Passerini et al., 2003). 543 
An IM exposure frequency-dependent decrease in follicle diameters was found at all 544 
follicle stages (Figs. 3f-j and 3f-j). The vascular network is essential for providing organs 545 
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with oxygen, nutrients, and hormones, as well as removing metabolic waste products (Haigh, 546 
2008; Kim et al., 2013). The vegf gene family provides required signals for vasculogenesis 547 
(de novo formation of blood vessels) during embryogenesis and for angiogenesis (formation 548 
of new blood vessels from preexisting vessels) during organogenesis (Kim et al., 2013). 549 
Bahary et al. (2007) isolated a duplicate vegfa locus in zebrafish (vegfaa and vegfab). vegfa 550 
expression has been correlated with the proliferation of blood vessels in the ovary in 551 
mammals (Phillips et al., 1990; Ravindranath et al., 1992; Kaczmarek et al., 2005). 552 
Folliculogenesis is dependent on new capillary vessel proliferation (Ferrara, 2004). McFee et 553 
al. (2009) and Artac et al. (2009) cited the involvement of vegfa in rat folliculogenesis. vegfa 554 
production in the ovary is critical for normal reproductive function in mammals (Geva and 555 
Jaffe, 2000). Oocyte size in adult fish at later ovary stages is determined by the uptake of 556 
systemic circulating vitellogenin (Vtg) protein. Vtg is synthesized and secreted by 557 
hepatocytes, transported to the ovary via blood, and finally deposited in oocytes as Vtg-558 
derived egg yolk proteins (Wallace, 1985; Arukwe and Goksøyr, 2003). Yolk proteins play a 559 
key biological role during embryogenesis and larvae development. The decrease in follicle 560 
size s in all follicular stages in IM-treated fish may be attributed to the reduction in 561 
angiogenesis (because of vegfaa down-regulation) that led to a decrease in availability of Vtg 562 
and maybe endocrine regulators.  563 
igf2 is also involved in angiogenesis (Herr et al., 2003), exerting its angiogenic effects 564 
both directly and via a vegfa mediated process (Belinsky et al., 2008). 565 
In the current study, a significant decrease in fecundity was observed in IM-treated zebrafish 566 
(section 3.5). In the study of Zhu et al. (2015) the number of produced eggs in zebrafish 567 
positively correlated with the level of ovary igf2a expression. igf2a is dynamically expressed 568 
during folliculogenesis in zebrafish (Li et al., 2015). Wang et al. (2011) suggested that 569 
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reduced egg production may reflect a defect in folliculogenesis. Therefore, the decreased 570 
fecundity observed here can be attributed to the IM-induced reduction in igf2a mRNA.  571 
Exposure of adult male zebrafish to IM led to an exposure frequency-dependent 572 
decrease in sperm density (Figs. 6a and 7a). The presence of igf2a in zebrafish testes has been 573 
cited by Irwin (2011), Nóbrega et al. (2015), Safian et al. (2016), and Teng et al. (2017). igf2 574 
has a selective paracrine or autocrine role in the regulation of spermatogonial proliferation 575 
during spermatogenesis (Gupta, 2005). In humans igf2 promotes the differentiation of 576 
spermatogonia into primary spermatocytes (Nakayama et al., 1999). The significant decrease 577 
in sperm density in IM-treated zebrafish may be attributed to the reduction in spermatogonial 578 
proliferation and differentiation due to testis igf2a down-regulation. 579 
IM-treated zebrafish had a lower number of motile sperm than (controls) (Fig. 6b-g). 580 
vegfa is present during testis morphogenesis and expressed by Sertoli cells which play an 581 
important role in testis formation and function in the human (Funke et al., 2010). Alterations 582 
in vegfa expression have frequently been correlated to testis developmental and functional 583 
impairments in the mouse (Korpelainen et al., 1998); rat (Bott et al., 2006; Baltes-Breitwisch 584 
et al., 2010) and human (Funke et al., 2010). The vegf protein is present in human spermatids, 585 
Sertoli and Leydig cells, and seminal plasma (Obermair et al., 1999). vegf has an important 586 
role in human and murine sperm physiology, maturation, and fertility (Obermair et al., 1999; 587 
Nalbandian et al., 2003). The effects of the protein on human sperm motility (Iyibozkurt, 588 
2008) and survival (Attar et al., 2005) have been cited. The inhibitory effect of IM on vegf 589 
expression was cited in mammals (Legros et al., 2004; Raimondi et al; 2014). The concurrent 590 
reduction in the number of motile sperm and vegfaa expression in IM-treated zebrafish testis 591 
in the current study suggest vegfaa down-regulation can be considered as one of reasons for 592 
sperm success failure.    593 
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Although we did not find a significant difference between IM-treated and untreated 594 
zebrafish concerning embryo-larvae survival in the current study (see section 3.7.3), we 595 
found significant MC ratio differences s (Table 1). It is clearly evident that igf2 is important 596 
during post-hatching development in teleosts, possibly as a local paracrine and/or autocrine 597 
regulator of tissue growth (Wood et al., 2005). IM-induced morphometric changes (Table 1) 598 
in the current study were detected in characteristics related to the longitudinal axis of larvae 599 
body, therefore the IM-induced changes in MC ratios can be attributed to igf2a down-600 
regulation. 601 
In conclusion, in the current study the same experimental setting was used for analysis 602 
of gamete quality and breeding and offspring studies. Our findings were very much in line 603 
with the few available experimental results cited for humans and other mammalian 604 
vertebrates. Here, for the first time a non-mammalian vertebrate was efficiently utilized to 605 
provide new data to help clarify the adverse effects of IM on the process of reproduction. In 606 
the current study the zebrafish model enabled us to further characterize IM-induced 607 
alterations in reproductive success. This suggests that zebrafish can be considered as a 608 
suitable laboratory model not only to explain conflicting data about the effects of TKIs (such 609 
as IM) on fertility and teratogenicity, but also to uncover underlying molecular mechanisms 610 
of TKI’s adverse effects reproductive processes. This follows the suggestion that zebrafish 611 
may help to establish a new path for improving fertility and treatment of ovarian disorders in 612 
vertebrates (Biswas and Maitra, 2017). 613 
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Tables  983 
Table 1. IM-induced changes in larval morphometric ratios.  984 
Footnote → Values superscripted with the same letter are not significantly different. See the 985 
legend of Figure 1 for abbreviations of the morphometric ratios. Number of specimens (n) = 986 
20. 987 
 988 
Table 2. Regression equations, correlation (r2), F and p values of the significant relationships 989 
found between the larval morphometric ratios and the frequency of exposure of adult 990 
zebrafish to IM.  991 
Footnote → The boldface and underlined data show morphometric ratios that are correlated 992 
to the frequency of exposure to IM by simple regression models in the form of a linear and 993 
quadratic function, respectively. See the legend of Figure 1 for abbreviations of the 994 















Fig. 1. Observation time points, whole-body zebrafish sagittal section, breeding trials, and 1008 
morphometric characteristics. (a) Observation time points of zebrafish embryos and larvae. (b) 1009 
Whole-body zebrafish, paraffin embedded, and H & E stained. Sagittal orientation, dorsal up. 1010 
S, swim bladder; O, ovary; L, liver; and I, intestine. (c-d) Breeding trials (IM-0♀ × IM-0♂ 1011 
[c] and IM-3♀ × IM-3♂ [d]). (e) Male replacement trial (IM-3♀ × IM-0♂). (f) Female 1012 
replacement trial (IM-0♀ × IM-3♂). (g-j) Morphometric characteristics determined in 1013 
zebrafish embryos and larvae. The landmarks drawn on the schematics of the zebrafish larvae 1014 
at 48, 72, 96, and 120 hpf depict the characteristics utilized for screening IM-induced 1015 
responses. BL (total body length): greatest horizontal body distance ― anterior-most part of 1016 
head to the end of body. APB (anterior part of the body): anterior-most part of head to the 1017 
posterior-most insertion of yolk sac. PoPB (posterior part of body): the posterior-most 1018 
insertion of yolk sac to the end of body. HL (head length): anterior-most part of head to the 1019 
place where the head is connected to the body. BD1 (body depth 1): vertical distance from 1020 
posterior-most insertion of yolk sac to upper surface of body. BD2 (body depth 2): greatest 1021 
vertical body distance. Fifteen ratios were calculated from the six morphometric 1022 
characteristics BL/APB, BL/PoPB, BL/BD1, BL/BD2, BL/HL, APB/PoPB, APB/BD1, 1023 
APB/BD1, APB/HL, PoPB/BD1, PoPB/BD2, PoPB/HL, BD1/BD2, BD1/HL, and BD1/HL. 1024 
 1025 
Fig. 2. Follicles at different gametogenic stages (a-h) and atretic follicles (i-l). (a) 1026 
Perinucleolus stage (PN); (b,c) early cortical alveolus stage (eCA); (d,e) mid-cortical alveolus 1027 
stage (mCA); (f-g) vitellogenic stage (V); (h) mature stage (M), and (i-l) examples of atretic 1028 




Fig. 3. Folliculogenesis in untreated (control) and IM-treated fish. Percentage (a, b, c, d, and 1031 
e) and diameter (μm; f, g, h, i, and j) of ovarian follicles at various gametogenic stages. See 1032 
the legend of Figure 2 for the abbreviation of follicular stages. Results that do not share the 1033 
same letter are significantly different.  n = 32. 1034 
 1035 
Fig. 4. Percentage (a, b, c, d, and e) and diameter (f, g, h, i, and j) of follicles at various stages 1036 
in relationship to the frequency of IM exposure. See the legend of Figure 2 for the 1037 
abbreviation of follicular stages. n = 32. 1038 
 1039 
Fig. 5. Folliculogenesis (percentage [a, b, c, d, and e] and diameter [f, g, h, i, and j] of 1040 
follicles) at termination of IM exposure (black bars) and after the 1-month depuration period 1041 
(IMD) (gray bars). See the legend of Figure 2 for the abbreviation of follicular stages. Results 1042 
that do not share the same letter are significantly different. n = 48. IM: the sum of IM-1, IM-2 1043 
and IM-3, IMD: the sum of IM-1, IM-2 and IM-3 after the one month depuration.  1044 
 1045 
Fig. 6. Sperm quality parameters in untreated (control) and IM-treated fish. Density, per mL, 1046 
(n = 35) (a) and motility (n = 20) at different “seconds post activation”, spa of sperm. Results 1047 
that do not share the same letter are significantly different.  1048 
 1049 
Fig. 7. Density, per mL, (n = 35) and motility (n = 20) of sperm in relationship with the 1050 
frequency of exposure to IM.  1051 
 1052 
 1053 
Table. 1. IM-induced changes in larval morphometric ratios.  
 
No.  Variables IM exposure frequency 
   0 1 2 3 
1  BL/BD1-72 9.33 ± 0.09b 8.80 ± 0.04a 8.75 ± 0.15a 9.68 ± 0.10c 
2  APB/BD1-72 3.61 ± 0.06b 3.52 ± 0.16bc 3.33 ± 0.11a 3.74 ± 0.11c 
3  BL/BD1-96 10.23 ± 0.09c 9.71 ± 0.11b 9.60 ± 0.22b 8.96 ± 0.03a 
4  APB/BD1-96 3.96 ± 0.05c 3.70 ± 0.14b 3.56 ± 0.07a 3.53 ± 0.07a 
5  APB/BD2-96 2.53 ± 0.06c 2.36 ± 0.07b 2.32 ± 0.05ab 2.25 ± 0.01a 
6  BL/BD1-120 11.70 ± 0.58d 10.13 ± 0.22a 10.04 ± 0.14a 10.83 ± 0.15b 
7  BL/APB-120 2.67 ± 0.05bc 2.63 ± 0.08ab 2.56 ± 0.05a 2.72 ± 0.04c 
8  BL/BD2-120 7.16 ± 0.24d 6.18 ± 0.45a 6.44 ± 0.11ab 6.68 ± 0.10b 
9  BL/HL-120 3.77 ± 0.11a 3.72 ± 0.05a 3.81 ± 0.11a 4.03 ± 0.05b 
10  PoPB/BD2-120 4.48 ± 0.13b 3.84 ± 0.34a 3.92 ± 0.16a 4.24 ± 0.03b 
11  BD2/HL-120 0.53 ± 0.02a 0.60 ± 0.04b 0.59 ± 0.01b 0.59 ± 0.02b 
12  BL/BD1-144 11.65 ± 0.15c 10.29 ± 0.47a 10.61 ± 0.17a 11.02 ± 0.11b 
13  BL/BD2-144 7.02 ± 0.25b 6.58 ± 0.28a 6.92 ± 0.09b 7.08 ± 0.07b 
14  PoPB/BD1-144 7.47 ± 0.08c 6.55 ± 0.14a 6.87 ± 0.38ab 6.97 ± 0.18b 
15  BD1/BD2-144 0.60 ± 0.01a 0.64 ± 0.01b 0.65 ± 0.02b 0.64 ± 0.02b 
16  BD1/HL-144 0.32 ± 0.02(a 0.36 ± 0.02b 0.35 ± 0.02b 0.35 ± 0.01ab 
17  BL/HL-168 3.74 ± 0.10a 4.03 ± 0.04c 3.87 ± 0.03b 3.69 ± 0.07a 
18  BL/BD1-168 10.59 ± 0.67a 11.32 ± 0.08b 11.47 ± 0.12b 11.27 ± 0.07b 
19  APB/HL-168 1.36 ± 0.09ab 1.47 ± 0.08b 1.44 ± 0.06ab 1.35 ± 0.04a 
20  BL/BD1-192 12.10 ± 0.33c 11.05 ± 0.31a 11.61 ± 0.11b 12.06 ± 0.06c 
21  APB/BD1-192 4.34 ± 0.08b 4.07 ± 0.04a 4.00 ± 0.04a 4.36 ± 0.14b 
22  APB/BD2-192 2.57 ± 0.05b 2.47 ± 0.08a 2.40 ± 0.04a 2.69 ± 0.05b 
23  BL/BD1-216 12.64 ± 0.40b 11.75 ± 0.22a 11.47 ± 0.29a 12.60 ± 0.13b 
24  BL/HL-240 3.76 ± 0.06a 3.78 ± 0.04a 4.06 ± 0.01b 4.08 ± 0.01b 
25  BL/BD1-240 11.48 ± 0.21a 11.76 ± 0.79ab 12.22 ± 0.29b 13.29 ± 0.15c 
26  PoPB/BD1-240 7.14 ± 0.13a 7.59 ± 0.43b 7.83 ± 0.04b 8.30 ± 0.14c 
Values superscripted with the same letter are not significantly different. n = 5 (for each 





Table 2. IM exposure frequency effect on larval morphometric ratios. Regression equations, 
correlation (r2), and F values of the significant relationships found between the larval 
morphometric ratios and the frequency of exposure of adult zebrafish to IM-0, IM-1, IM-2, and 
IM-3.  
 
No.  Variables Equation r2 F 
  Independent    
1  BL/BD1-72 y = 0.365x2 - 0.995x + 9.354 0.933 90.440 
2  IPB/BD1-72 y = 0.018x + 3.522 0.013 0.183 
3  BL/BD1-96 y = -0.392x + 10.213 0.881 103.998 
4  IPB/BD1-96 y = -0.144x + 3.901 0.742 40.186 
5  IPB/BD2-96 y = -0.088x + 2.497 0.758 43.787 
6  BL/BD1-120 y = 0.591x2 - 2.046x + 11.672 0.839 33.842 
7  BL/IPB-120 y = 0.010x + 2.630 0.021 0.299 
8  BL/BD2-120 y = 0.306x2 - 1.038x + 7.097 0.609 10.132 
9  BL/HL-120 y = 0.090x + 3.696 0.491 13.490 
10  PoPB/BD2-120 y = 0.241x2 - 0.788x + 4.453 0.665 12.912 
11  BD2/HL-120 y =-0.020x2 + 0.077x + 0.532 0.600 9.750 
12  BL/BD1-144 y = 0.443x2 - 1.484x + 11.568 0.726 17.263 
13  BL/BD2-144 y = 0.051x + 6.820 0.050 0.743 
14  PoPB/BD1-144 y = -0.116x + 7.139 0.114 1.809 
15  BD1/BD2-144 y = -0.012x2 + 0.049x + 0.603 0.620 10.600 
16  BD1/HL-144 y = 0.007x + 0.335 0.120 1.901 
17  BL/HL-168 y = -0.117x2 + 0.321x + 3.757 0.723 17.006 
18  BL/BD1-168 y = 0.217x + 10.835 0.290 5.707 
19  IPB/HL-168 y = -0.008x + 1.415 0.015 0.213 
20  BL/BD1-192 y = 0.376x2 - 1.081x + 12.013 0.650 12.098 
21  IPB/BD1-192 y = 0.157x2 - 0.471x + 4.348 0.799 25.857 
22  IPB/BD2-192 y = 0.097x2 - 0.263x+2.581 0.074 18.429 
23  BL/BD1-216 y = 0.505x2 - 1.555x + 12.677 0.798 25.745 
24  BL/HL-240 y = 0.122x + 3.738 0.813 61.022 
25  BL/BD1-240 y = 0.587x + 11.309 0.699 32.584 
26  PoPB/BD1-240 y = 0.371x + 7.159 0.798 55.337 
 
See figure 1 legend for morphometric ratio abbreviations. Number of specimens = 20. 
 
 
 







